Description
Anti-GD2 immunotherapy: A Game Changer in High-Risk Neuroblastoma
Livestream Webinar via Zoom
Date: September 3, 2025
Time: 1:00 PM EST (10:00 AM PST, 11:00 AM MST, 12:00 PM CST)
Presented by:
- Kristen L Dalton MSN RN CPNP-AC CPHON
- Linda D’Andrea, MSN, RN, PPCNP-BC, CPHON
Overview of Session: This webinar delves into the advanced use of anti-GD2 immunotherapies in the treatment of high-risk neuroblastoma. Participants will explore the purpose and pathophysiology of these therapies, supported by current literature. The session will distinguish between Dinutuximab and Naxitamab, focusing on their administration, timelines, and adverse event management. Additionally, nursing implications for patients receiving anti-GD2 therapies will be discussed, along with recent advances in administration and management, including institutional pathways, open protocols, and future directions. Finally, the coordination of care and resources necessary for successful anti-GD2 immunotherapy utilization will be addressed.
This Session will Explore:
- Advanced Use of Anti-GD2 Immunotherapies:Â Understand the purpose and pathophysiology of anti-GD2 therapies in treating high-risk neuroblastoma.
- Dinutuximab vs. Naxitamab:Â Learn the differences in administration, timelines, and adverse event management between these two therapies.
- Nursing Implications:Â Gain insights into the nursing implications for patients receiving anti-GD2 therapies.
- Recent Advances:Â Explore recent advances in administration and management, including institutional pathways, open protocols, and future directions.
- Coordination of Care:Â Learn about the coordination of care and resources necessary for successful anti-GD2 immunotherapy utilization.
*NOTE: Webinar recording link and evaluation are located in “My Courses- ACE Center” after registration is complete
Upon successful completion of this course, nurses will earn 1 NCPD. There are
.25 pharmacology hours associated with this activity.
Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Provider approved by the California Board of Registered Nursing, Provider Number 14513.
Individual Learning Needs Assessment (ILNA) Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. You may claim 1 NCPD in one of the following ILNA categories: Care Continuum, Psychosocial Dimensions of Care, OR Care of the Pediatric Hem/Onc PatientÂ
Please reach out to the Education Team at education@aphon.org with your name, the email associated with your APHON account, and the above ILNA category you would like to have reflected on your certificate and APHON can update your completion certificate to reflect your choice.
Any questions? Contact education@aphon.org
